The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2009Accurate Drosophila Genetic Models of LRRK2-based Parkinson's Disease
Objective/Rationale:
The most common hereditary form of Parkinson’s Disease (PD) results from mutations of the LRRK2 gene in humans. The model genetic organism, Drosophila melanogaster (fruit fly)... -
Rapid Response Innovation Awards, 2009Uncovering Factors that Prevent Dopaminergic Neuronal Degeneration in a Novel C. elegans Model for Parkinson's Disease using a High-throughput Forward Genetics Approach
Objective/Rationale:
Our inability to slow down the progression of Parkinson’s disease (PD) reflects our incomplete knowledge of the molecular mechanisms that cause the selective death of dopaminergic... -
Clinical Intervention Awards, 2009MASTER PD: Magnetic Stimulation for the Treatment of Motor and Mood Symptoms of Parkinson's Disease: A Four-Center, Sham-Controlled, Parallel Group Study
Objective/Rationale:
To determine the efficacy and duration of benefit of noninvasive brain stimulation with repetitive transcranial magnetic stimulation (rTMS) to modulate brain activity in order to... -
Clinical Intervention Awards, 2009SING-PD: Singing In Groups for Parkinson's Disease: A Phase I/II Study of Choral Therapy for PD-related Voice/Speech Impairment
Objective/Rationale:
To compare two forms of speech and voice therapy (one involving breathing and speech exercises and the other involving singing in groups) to see which type of therapy is better in... -
Clinical Intervention Awards, 2009Naltrexone for Impulse Control Disorders in Parkinson's Disease
Objective/Rationale:
This is the first controlled trial of an agent to treat impulse control disorders (ICDs) in Parkinson’s disease (PD). Naltrexone, which blocks opioid receptors, is FDA-approved... -
Clinical Intervention Awards, 2009Eltoprazine for Treatment of Levodopa-induced Dyskinesias
Objective/Rationale:
Researchers have identified a new potential drug target — receptors located on the serotonin neurons in the brain — for alleviation of involuntary movements, dyskinesias, in...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.